Biogen Builds Out Parkinson's Pipeline With Denali Deal

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.

PARTNERS word made with building blocks
Biogen and Denali are teaming up in Parkinson's disease • Source: Shutterstock

Biogen, Inc. is doubling down in the Parkinson's disease therapeutic area through a new partnership with Denali Therapeutics Inc. in which it will gain co-development and co-commercialization rights to Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Biogen has promised investors it would build out its clinical-stage pipeline through deal-making this year as it seeks to diversify the portfolio beyond Tecfidera (dimethyl fumarate) and Spinraza (nusinersen).

The two companies announced the deal on 6 August, with Biogen agreeing to pay Denali $560m up front plus a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.